Details:
On acquisition, Partners Group will work to strengthen Pharmathen’s business in Europe and the US, especially R&D, sustained release’ technologies, including long-acting injectables, slow-releasing oral drugs and ophthalmics segment.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Partners Group
Deal Size: $1,900.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 19, 2021